Innovation Pharmaceuticals Inc (IPIX)

[Here Today]

Unless I am mistaken, the license agreement was for the enema application of Brilacidin use.

In my opinion, I’m not sure they would want to continue to go that route and as such might choose to go the route of oral application instead which to me would mean termination of existing agreement and retry for a new agreement. Alfasigma should have pursued both routes at the same time of signing the original cheaper licensing deal especially since they now know it can be given intravenously.

Hopefully Leo can put out a further more clarifying PR once Alfasigma confirms what they wish to do.